百济神州(ONC)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ONC 百济神州

盘前交易 07-29 05:30:06 EDT

294.51

+3.04

+1.04%

盘前307.08

+12.57+4.27%

05:04 EDT

最高299.90	最低294.39	成交量40.44万
今开299.00	昨收291.47	日振幅1.89%
总市值349.44亿	流通市值222.48亿	总股本1.19亿
成交额1.20亿	换手率0.54%	流通股本7,554万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ONC","market":"US","secType":"STK","nameCN":"百济神州","latestPrice":294.51,"timestamp":1753732800000,"preClose":291.47,"halted":0,"volume":404449,"hourTrading":{"tag":"盘前","latestPrice":307.08,"preClose":294.51,"latestTime":"05:04 EDT","volume":404,"amount":124262.44120000002,"timestamp":1753779876240},"delay":0,"floatShares":75541600,"shares":118650120,"eps":-3.70325,"marketStatus":"盘前交易","change":3.04,"latestTime":"07-29 05:30:06 EDT","open":299,"high":299.9,"low":294.39,"amount":120087581.5085,"amplitude":0.018904,"askPrice":307,"askSize":30,"bidPrice":306.3,"bidSize":50,"shortable":3,"etf":0,"ttmEps":-3.70325,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1753795800000},"marketStatusCode":1,"adr":0,"adrRate":13,"exchange":"NASDAQ","adjPreClose":294.51,"preHourTrading":{"tag":"盘前","latestPrice":307.08,"preClose":294.51,"latestTime":"05:04 EDT","volume":404,"amount":124262.44120000002,"timestamp":1753779876240},"postHourTrading":{"tag":"盘后","latestPrice":294.51,"preClose":294.51,"latestTime":"19:50 EDT","volume":3320,"amount":977767.59,"timestamp":1753746639095},"volumeRatio":1.451192171898741,"impliedVol":0.4413,"impliedVolPercentile":0.6596},"requestUrl":"/m/hq/s/ONC","defaultTab":"news","newsList":[{"id":"2555039011","title":"一线疗法！百济神州/安进在国内启动 DLL3/CD3 双抗新 III 期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2555039011","media":"Insight数据库","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555039011?lang=zh_cn&edition=full","pubTime":"2025-07-29 17:05","pubTimestamp":1753779943,"startTime":"0","endTime":"0","summary":"7 月 28 日，药物临床试验登记与信息公示平台显示，百济神州/安进登记了一项Tarlatamab用于未经治疗的广泛期小细胞肺癌患者的 III 期临床。塔拉妥单抗是一款由安进公司研发的创新靶向免疫疗法，能够同时结合肿瘤细胞上的 DLL3 蛋白和 T 细胞上的 CD3 蛋白，进而激活 T 细胞来杀伤表达 DLL3 蛋白的肿瘤细胞。其中，三线疗法已于日前在国内报上市并已进入优先审评通道。该研究旨在评估其用于 SCLC 二线治疗的疗效。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729171949a4696069&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729171949a4696069&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4581","IE0009355771.USD","BK4585","BK4139","BK4534","BK4566","LU1057294990.SGD","IE00B2B36J28.USD","BK4588","LU2242646821.SGD","III","LU1983299246.USD","LU2468319806.SGD","AMGN","LU0868494617.USD","SG9999001440.SGD","LU0122379950.USD","LU0289739699.SGD","LU0889565916.HKD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","BK4134","LU1571399168.USD","ONC","BK4599","LU2089984988.USD","IE00BJJMRZ35.SGD","BK4526","LU1023059063.AUD","IE0002141913.USD","LU1061106388.HKD","LU0058720904.USD","LU0109394709.USD","LU2242652126.USD","LU2112291526.USD","BK4533","IE00B4R5TH58.HKD","LU0320765992.SGD"],"gpt_icon":0},{"id":"2555035386","title":"港股收评：午后回升！恒指小幅下跌0.15%，创新药涨幅抢眼，三胎概念股高开低走","url":"https://stock-news.laohu8.com/highlight/detail?id=2555035386","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555035386?lang=zh_cn&edition=full","pubTime":"2025-07-29 16:21","pubTimestamp":1753777290,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["METmain","09618","601288","06160","161726","HSCEI","MPNGY","BIDU","01024","02359","159992","BABA","03690","01398","TTTN","HHImain","03086","07226","MHImain","YANG","601939","JD","TCHmain","KSTmain","603259","01288","01810","HSI","HSImain","TCEHY","08496","MCHmain","HTCD.SI","02186","01530","399441","MIUmain","01801","688428","HSTECH","09969","601398","00700","01093","ONC","00939","688235","ALBmain","06978"],"gpt_icon":0},{"id":"2555038763","title":"基金二季报陆续披露，中欧葛兰等基金经理加码创新药板块","url":"https://stock-news.laohu8.com/highlight/detail?id=2555038763","media":"全景网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555038763?lang=zh_cn&edition=full","pubTime":"2025-07-29 15:19","pubTimestamp":1753773595,"startTime":"0","endTime":"0","summary":"随着基金二季报陆续披露， 创新药 板块成为众多基金经理关注的焦点，葛兰、谢治宇、傅鹏博、高楠等基金经理也纷纷加码创新药板块。展望三季度，在创新药领域，中欧基金葛兰在二季报中表示，看好全球合作深化与重要临床数据披露预期。睿远基金傅鹏博在二季度增加了医药板块配置，涉及创新药等子行业；永赢基金高楠管理的永赢睿信，在将 康方生物 、百济神州- U买进重仓股后，还在继续加码创新药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729152818a4691f68&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729152818a4691f68&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09926","ONC","BK4526","06160","BK4139","01801"],"gpt_icon":0},{"id":"2555081042","title":"百济神州7月28日成交额为1.20亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2555081042","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555081042?lang=zh_cn&edition=full","pubTime":"2025-07-29 12:53","pubTimestamp":1753764818,"startTime":"0","endTime":"0","summary":"美东时间2025年7月28日，百济神州成交额为1.20亿美元，成交额较昨日增加140.67%，当日成交量为40.44万股。百济神州于2025年7月28日涨1.04%，报294.51美元，该股过去5个交易日涨0.88%，年初至今涨59.44%，过去60日涨13.36%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729125344a6c71fba&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729125344a6c71fba&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ONC","BK4526"],"gpt_icon":0},{"id":"2555866160","title":"百济神州：百泽安获欧洲药品管理局人用药品委员会积极意见","url":"https://stock-news.laohu8.com/highlight/detail?id=2555866160","media":"智通财经","labels":["productRelease"],"top":1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555866160?lang=zh_cn&edition=full","pubTime":"2025-07-29 10:45","pubTimestamp":1753757135,"startTime":"0","endTime":"0","summary":"7月29日，据$百济神州$官微消息，7月28日，公司宣布欧洲药品管理局人用药品委员会发布积极意见，推荐批准百泽安联合含铂化疗用于存在高复发风险的可切除非小细胞肺癌成人患者的术前新辅助治疗，并在术后继续使用替雷利珠单抗单药进行辅助治疗。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1322972.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"百济神州：百泽安获欧洲药品管理局人用药品委员会积极意见","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","688235","BK4526","BK4087","06160","LU0588546209.SGD","BK0239","BK1500","LU2328871848.SGD","ONC","BK4139","BK1583","BK1588","LU1969619763.USD","LU0307460666.USD"],"gpt_icon":0},{"id":"2555704118","title":"国内稀缺、研发实力强！7家创新药企手握重磅新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2555704118","media":"巨丰投顾","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555704118?lang=zh_cn&edition=full","pubTime":"2025-07-29 05:59","pubTimestamp":1753739961,"startTime":"0","endTime":"0","summary":"核心龙头业绩高速增长提及恒瑞医药上涨10%。创新药作为医药生物板块的核心投资主线，近期在政策、市场等多方面迎来积极变化。受益于海外订单的持续增长以及国内创新药研发的提速，这些企业整体盈利能力和成长性得到提升，2025年上半年业绩表现超出市场预期。2025年上半年创新药收入占比超45%，半年报业绩预增，其HER2 ADC药物临床数据优于同类产品，有望成为重磅炸弹级产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729060051a46849a2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"3dc301cf42325347990d1936e0b8178f","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729060051a46849a2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01877","01276","06160","BK4139","BK4526","688235","600276","ONC","688180"],"gpt_icon":0},{"id":"2554783067","title":"百济神州百泽安®获欧洲药品管理局人用药品委员会积极意见，支持其用于非小细胞肺癌患者新辅助/辅助治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2554783067","media":"百济神州","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554783067?lang=zh_cn&edition=full","pubTime":"2025-07-28 18:04","pubTimestamp":1753697071,"startTime":"0","endTime":"0","summary":"此次CHMP的积极意见将有望惠及处在更早期治疗阶段的患者。百泽安是百济神州实体瘤产品组合的基石药物，已在多种肿瘤类型和疾病中展现出潜力。百泽安已在46个国家和地区获批，全球超过150万例患者接受了治疗。关于百济神州百济神州是一家注册地位于瑞士的全球肿瘤治疗创新公司，专注于为全世界的癌症患者研发创新抗肿瘤药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250728180959a6c5c7be&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250728180959a6c5c7be&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","06160","BK4526","ONC"],"gpt_icon":0},{"id":"2554476027","title":"港股异动 | 百奥赛图-B(02315)涨超3% 近日宣布与百济神州达成抗体分子全球许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2554476027","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554476027?lang=zh_cn&edition=full","pubTime":"2025-07-28 11:20","pubTimestamp":1753672815,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，百奥赛图-B涨超3%，截至发稿，涨2.64%，报21.35港元，成交额450.75万港元。消息面上，近日，据百奥赛图官微消息，公司宣布与全球肿瘤治疗创新公司百济神州达成抗体分子的全球许可协议。根据协议条款，百济神州将向百奥赛图支付首付款。据介绍，百济神州此前已获得百奥赛图RenMice全人抗体平台的授权使用许可，本次双方在已建立的良好合作基础上进一步将合作拓展至抗体分子授权许可领域，标志着双方合作的持续深化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1322457.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","02315","LU2328871848.SGD","BK1583","BK4139","BK1500","BK4526","LU1969619763.USD","LU0307460666.USD","06160","BK1161","LU0588546209.SGD","688235","ONC","BK1588"],"gpt_icon":0},{"id":"2554877817","title":"百济神州-U股价微跌0.19% 二季度获201家基金重仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2554877817","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554877817?lang=zh_cn&edition=full","pubTime":"2025-07-25 02:33","pubTimestamp":1753382029,"startTime":"0","endTime":"0","summary":"截至2025年7月24日收盘，百济神州-U股价报237.68元，较前一交易日下跌0.45元，跌幅0.19%。当日成交量为21877手，成交金额达5.20亿元。百济神州-U属于医药生物行业，是一家专注于创新药物研发的生物科技企业。公司主要从事肿瘤、免疫肿瘤等领域的创新药物研发、生产和商业化。数据显示，2025年二季度末共有201家基金重仓持有百济神州-U，合计持股3850.52万股，占流通股比例达33.47%。在科创板公司中，百济神州-U的基金持股比例排名第二。7月24日，百济神州-U主力资金净流出453.23万元，占流通市值比例为0.02%。风险提示：投资有风险，入市需谨慎。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725023955971c9964&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725023955971c9964&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","BK0239","06160","ONC"],"gpt_icon":0},{"id":"2553078322","title":"新事丨罗氏终止TIGIT全部三期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2553078322","media":"健识局","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553078322?lang=zh_cn&edition=full","pubTime":"2025-07-24 20:30","pubTimestamp":1753360205,"startTime":"0","endTime":"0","summary":"在最新的管线中，PD-1联合TIGIT治疗非小细胞肺癌、肝癌的三期临床均已终止。这意味着罗氏针对TIGIT进行的三期临床全部终止。TIGIT靶点的价值是罗氏在2009年最先发现的。当时，罗氏的TIGIT+PD-L1联合疗法的效果曾一鸣惊人，一度被认为是PD-1之后的免疫新星。全球范围内，这几年TIGIT单抗预期快速变化：默沙东、罗氏等药企都已经历多次失败，留给TIGIT靶点成功的希望相当渺茫。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724203245a6bfb977&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724203245a6bfb977&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MRK","BK0060","LU1997244956.HKD","01276","688266","BK0183","LU1655091616.SGD","BK0239","LU0405327148.USD","LU1997245177.USD","LU1997245094.SGD","688235","LU1328615791.USD","600276","LU2495084118.USD","BK0028","01801","BK0012","LU2148510915.USD","LU1969619763.USD","BK0188","688177","BK0196","06160","LU1064131003.USD","LU2328871848.SGD","LU0405327494.USD","LU2488822045.USD","ONC","LU1064130708.USD"],"gpt_icon":1},{"id":"2553216134","title":"百济潜在 BIC 蛋白降解剂获批新临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2553216134","media":"Insight数据库","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553216134?lang=zh_cn&edition=full","pubTime":"2025-07-23 16:28","pubTimestamp":1753259310,"startTime":"0","endTime":"0","summary":"7 月 23 日，CDE 官网显示，百济神州BGB-45035 片获批临床，用于治疗类风湿性关节炎。这是继特应性皮炎和结节性痒疹后，BGB-45035 获批的第三项临床。来源：CDE 官网BGB-45035 是一款靶向白细胞介素 1 受体相关激酶4的 蛋白降解剂。据百济介绍，BGB-45035 具有同类最佳潜力，在临床前模型中，相比 KT474，BGB-45035 可带来更快、更深度的 IRAK4 降解，且细胞因子抑制作用更强。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250723173827a6bd0654&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250723173827a6bd0654&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","BK0239","ONC","06160"],"gpt_icon":0},{"id":"2553575942","title":"券商资管系公募，排名来了！","url":"https://stock-news.laohu8.com/highlight/detail?id=2553575942","media":"中国基金报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553575942?lang=zh_cn&edition=full","pubTime":"2025-07-23 00:06","pubTimestamp":1753200372,"startTime":"0","endTime":"0","summary":"头部券商资管公募管理规模普遍增长Wind数据显示，截至二季度末，共有4家券商资管机构的公募基金资产管理总规模超千亿元。此外，相比于今年一季度末，头部券商资管的公募管理规模普遍增长，东方红资产管理、华泰证券资管规模增长均超200亿元，招商证券资管规模增长33亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250723001401a45cdc20&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250723001401a45cdc20&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","688443","ONC","01276","600276","688192","BK0239","688266","06160","09969","06990","688428"],"gpt_icon":0},{"id":"2553008144","title":"公募基金2025年二季报全扫描【国信金工】","url":"https://stock-news.laohu8.com/highlight/detail?id=2553008144","media":"量化藏经阁","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553008144?lang=zh_cn&edition=full","pubTime":"2025-07-22 08:06","pubTimestamp":1753142805,"startTime":"0","endTime":"0","summary":"一基金仓位监控在跟踪基金仓位变化时，由于2015年四季度以前股票型基金仓位规定下限为60%，在这之后规定为80%。截至2025年二季报，科技类板块配置权重依旧最高，最新一期配置权重为37.42%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722082610a6b94be8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722082610a6b94be8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600519","688235","YANG","688428","BK4585","BYDDY","ONC","BK4588","09988","BK4099","BK4614","03750","09969","EVS.SI"],"gpt_icon":0},{"id":"2552626304","title":"百济神州(ONC)盘前涨近4% 机构料公司第二季收入按年升33%至12亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2552626304","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552626304?lang=zh_cn&edition=full","pubTime":"2025-07-18 19:26","pubTimestamp":1752837999,"startTime":"0","endTime":"0","summary":"金吾财讯 | 百济神州(ONC)盘前涨近4%，截至发稿，报301.260美元 。 消息面上，野村发表报告，料百济神州第二季收入按年升33%至12亿美元，与市场预期一致。该行预测百悦泽维持市场领导地位，次季销售按年升39%至8.84亿美元，其中美欧销售分别按年升35%及80%，至6.47亿及1.4亿美元。百泽安内地市场销售料按年升15%至1.82亿美元。此外，摩根大通分析师Jessica Fye维持百济神州买入评级，并将目标价从321美元上调至345美元。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250107/MzZmY2I0ODMyNDljNDZhYjk1YmMwYzA2ZTYzZmI3NWMyMTczNjIzMDYxMjY4Mg==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/MzZmY2I0ODMyNDljNDZhYjk1YmMwYzA2ZTYzZmI3NWMyMTczNjIzMDYxMjY4Mg==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"290592","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","LU0307460666.USD","BK1583","BK4526","LU0588546209.SGD","LU1969619763.USD","LU2328871848.SGD","688235","06160","BK4139","BK1500","BK1161","ONC","BK1588"],"gpt_icon":0},{"id":"2552459051","title":"百济神州7月17日成交额为2.34亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2552459051","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552459051?lang=zh_cn&edition=full","pubTime":"2025-07-18 12:31","pubTimestamp":1752813112,"startTime":"0","endTime":"0","summary":"美东时间2025年7月17日，百济神州成交额为2.34亿美元，成交额较昨日增加72.38%，当日成交量为80.49万股。百济神州于2025年7月17日涨4.01%，报290.35美元，该股过去5个交易日涨14.59%，年初至今涨57.19%，过去60日涨26.67%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250718123153a6b135fa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250718123153a6b135fa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4526","ONC"],"gpt_icon":0},{"id":"2552412721","title":"百济神州-U股价微跌0.56% 生物制药板块活跃度受关注","url":"https://stock-news.laohu8.com/highlight/detail?id=2552412721","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552412721?lang=zh_cn&edition=full","pubTime":"2025-07-17 01:56","pubTimestamp":1752688566,"startTime":"0","endTime":"0","summary":"百济神州-U7月16日收盘报239.94元，较前一交易日下跌0.56%。当日股价波动区间为237.79元至246.28元，成交金额达5.01亿元。该公司属于生物制品行业，专注于创新型分子靶向药物和肿瘤免疫药物的研发。作为一家全球性生物科技公司，百济神州在肿瘤治疗领域拥有多个在研产品管线。7月16日数据显示，百济神州-U主力资金净流出2927.45万元。该股当前总市值为3694.74亿元，流通市值276.06亿元。风险提示：股市有风险，投资需谨慎。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071702031197a8b94d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071702031197a8b94d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06160","ONC","BK0239","688235"],"gpt_icon":0},{"id":"2551140802","title":"小细胞肺癌或将迎来首个BiTE新疗法，百济神州塔拉妥单抗申报上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2551140802","media":"新浪医药","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551140802?lang=zh_cn&edition=full","pubTime":"2025-07-16 19:15","pubTimestamp":1752664513,"startTime":"0","endTime":"0","summary":"2025年7月16日，国家药品监督管理局药品审评中心网站显示，百济神州的注射用塔拉妥单抗上市申报获受理。SCLC约占所有肺癌病例的15%,，其中大约70%的SCLC患者初始诊断时即为ES-SCLC。据悉，塔拉妥单抗由安进公司研发。未来，双方将继续拓展塔拉妥单抗的应用范围，加速更多适应症申报上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716192041a44e9ea7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716192041a44e9ea7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4526","688235","ONC","BK4139","06160"],"gpt_icon":0},{"id":"2551576142","title":"高管减持迪哲医药另一面：全球化战略会是下个百济神州吗？【医药视界】","url":"https://stock-news.laohu8.com/highlight/detail?id=2551576142","media":"投资者网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551576142?lang=zh_cn&edition=full","pubTime":"2025-07-16 18:01","pubTimestamp":1752660075,"startTime":"0","endTime":"0","summary":"减持释放什么信号迪哲医药进入一个高层减持密集期。其中，吴清漪减持金额超1900万元，股份来源于股权激励及二级市场增持。截至目前，公司仍无控股股东、实际控制人。获批上市后，该药被成功纳入医保。公司表示，两款药品纳入医保目录后，销量大幅增加。最为市场熟知的，是百济神州的泽布替尼。受此因素，该药成功在欧美获批上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716180622a6ad36ff&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716180622a6ad36ff&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","06160","688192","ONC","688235","BK4526"],"gpt_icon":0},{"id":"2551149731","title":"百济神州7月15日成交额为1.81亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2551149731","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551149731?lang=zh_cn&edition=full","pubTime":"2025-07-16 12:39","pubTimestamp":1752640775,"startTime":"0","endTime":"0","summary":"美东时间2025年7月15日，百济神州成交额为1.81亿美元，成交额较昨日增加575.75%，当日成交量为67.44万股。百济神州于2025年7月15日涨6.96%，报269.7美元，该股过去5个交易日涨10.32%，年初至今涨46.01%，过去60日涨18.22%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716123942a44dcfb2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716123942a44dcfb2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4526","BK4139","ONC"],"gpt_icon":0},{"id":"2551119280","title":"科创成长层改革推进 券商系统升级及风险揭示书签署有序展开","url":"https://stock-news.laohu8.com/highlight/detail?id=2551119280","media":"DoNews","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551119280?lang=zh_cn&edition=full","pubTime":"2025-07-16 11:13","pubTimestamp":1752635582,"startTime":"0","endTime":"0","summary":"上交所方面正组织风险揭示书签署工作，并修订相关指南，新增《科创板科创成长层企业股票投资风险揭示书必备条款》，明确未盈利企业存在的各类投资风险。上交所下发通知要求券商完善适当性管理工作，包括完成风险揭示书签署及系统准备，给予投资者充分阅读时间，并通过多种渠道开展投资者教育。上交所将持续督促券商并开展监督检查。7月14日，上交所举办专题培训会，120家券商330余名相关负责人参会。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071611164495444cb2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071611164495444cb2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688443","688373","06160","688277","688512","688382","688327","688220","BK0239","000690.SH","688322","688549","688165","688176","688343","688221","688387","688515","688192","688266","688197","02402","688469","01877","688538","688302","09969","688280","ONC","688316","688256","688702","688561"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.beonemedicines.com","stockEarnings":[{"period":"1week","weight":0.0088},{"period":"1month","weight":0.221},{"period":"3month","weight":0.1791},{"period":"6month","weight":0.2991},{"period":"1year","weight":0.8119},{"period":"ytd","weight":0.5944}],"compareEarnings":[{"period":"1week","weight":0.013},{"period":"1month","weight":0.0358},{"period":"3month","weight":0.149},{"period":"6month","weight":0.0584},{"period":"1year","weight":0.1699},{"period":"ytd","weight":0.0868}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"　　百济神州有限公司的主营业务是研究、开发、生产以及商业化创新型药物。公司的主要产品是百悦泽、百泽安、百汇泽、安加维、倍利妥、凯洛斯、萨温珂、凯泽百、普贝希（安维汀生物类似药）、百拓维（注射用戈舍瑞林微球）、泰菲乐（达拉非尼）、迈吉宁（曲美替尼）、维全特（帕唑帕尼）、飞尼妥（依维莫司）、赞可达（塞瑞替尼）。","yearOnYearQuotes":[{"month":1,"riseRate":0.555556,"avgChangeRate":0.079635},{"month":2,"riseRate":0.666667,"avgChangeRate":0.038229},{"month":3,"riseRate":0.4,"avgChangeRate":-0.025903},{"month":4,"riseRate":0.4,"avgChangeRate":0.021288},{"month":5,"riseRate":0.4,"avgChangeRate":-0.019094},{"month":6,"riseRate":0.5,"avgChangeRate":0.012468},{"month":7,"riseRate":0.8,"avgChangeRate":0.144474},{"month":8,"riseRate":0.555556,"avgChangeRate":0.036185},{"month":9,"riseRate":0.555556,"avgChangeRate":0.064683},{"month":10,"riseRate":0.555556,"avgChangeRate":0.004837},{"month":11,"riseRate":0.555556,"avgChangeRate":0.060012},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.03651}],"exchange":"NASDAQ","name":"百济神州","nameEN":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.4","shortVersion":"4.34.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百济神州(ONC)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百济神州(ONC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百济神州,ONC,百济神州股票,百济神州股票老虎,百济神州股票老虎国际,百济神州行情,百济神州股票行情,百济神州股价,百济神州股市,百济神州股票价格,百济神州股票交易,百济神州股票购买,百济神州股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百济神州(ONC)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百济神州(ONC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}